Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
RAPP Stock Chart & Stats
$24.87
-$0.34(-1.94%)
At close: 4:00 PM EST
$24.87
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$6.43 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)1.36M
Market Cap
$1.15B
Enterprise Value$154.32M
Total Cash (Recent Filing)$260.45M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 06, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding46,113,304
10 Day Avg. Volume412,896
30 Day Avg. Volume1,355,761
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue214.33
Enterprise Value/Gross Profit-1.13K
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$52.00Price Target Upside109.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRAP-219 surpasses expectations with a 71% reduction in LE and 78% reduction in clinical seizures, providing strong evidence of its potential to become a mainstay in the treatment of FOS.
Market OpportunityWith about 30% of epilepsy patients refractory to treatment, significant unmet need remains, indicating potential room for new drugs with improved tolerability profiles.
Trial ResultsRapport Therapeutics announced positive topline results from the Phase IIa trial of RAP-219 in focal seizures.
Bears Say
Administration ChallengesThe 8-14 day half-life of RAP-219 may not be desirable due to the time it takes to reach steady-state.
PharmacokineticsDr. Anschel noted a potential concern with the 8-14 day half-life of RAP-219, as it may take a long time to reach a steady state.
Potential Side EffectsDr. Anschel expressed concern about the potential impact of RAP-219 on memory and will be monitoring for this adverse effect as more clinical data accrues.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.15B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 19 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.064.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.78.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 46,113,304 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went up 5.476%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (109.09% Upside)
$52.00 (109.09% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 684.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.7%
Last 30 Days ▲ 129.3%
Last 30 Days ▲ 129.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.91%
12-Months-Change
Fundamentals
Return on Equity
-29.42%
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$52.00
▲(109.09% Upside)
Technical Analysis
Ownership Overview
7.17% Insiders
24.17% Mutual Funds
0.03% Other Institutional Investors
63.22% Public Companies and
Individual Investors